Actos Tablets specified drug-use survey <Survey on glycemic control in type 2 diabetic patients with a history of cerebral infarction>

TAKEDA PHARMACEUTICAL COMPANY LTD.0 sites500 target enrollmentStarted: June 10, 2014Last updated: October 17, 2023

Trial Snapshot

No summary available.

•Type 2 diabetic patients with a prior history of cerebral infarction who meet all the following conditions, [1] to [3], at the time of enrollment in the survey:
•[1] First onset of cerebral infarction was at least 24 weeks prior to enrollment
•[2] HbA1c values >= 6.5% within 12 weeks prior to the start of treatment with Actos Tablets
•[3] No prior history of treatment with Actos Tablets since the first onset of cerebral infarction

•Patients who meet any of the following conditions, [1] to [5], shall be excluded from the survey:
•[1] Contraindication for Actos Tablets
•[2] Prior history of recurrence of cerebral infarction
•[3] Prior history of cerebral hemorrhage or subarachnoid hemorrhage
•[4] Complications or prior history of myocardial infarction, angina pectoris, cardiomyopathy, hypertensive heart disease, atrial fibrillation, atrial flutter, or valvular disease
•[5] Reduced cardiac function (defined as an ejection fraction [EF] <= 40%)

Sponsor

TAKEDA PHARMACEUTICAL COMPANY LTD.